FI3445351T3 - Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen - Google Patents
Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen Download PDFInfo
- Publication number
- FI3445351T3 FI3445351T3 FIEP17719692.0T FI17719692T FI3445351T3 FI 3445351 T3 FI3445351 T3 FI 3445351T3 FI 17719692 T FI17719692 T FI 17719692T FI 3445351 T3 FI3445351 T3 FI 3445351T3
- Authority
- FI
- Finland
- Prior art keywords
- acetylleucine
- pharmaceutically acceptable
- acceptable salt
- method comprises
- comprises administering
- Prior art date
Links
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 title claims 16
- 229960000669 acetylleucine Drugs 0.000 title claims 16
- 150000003839 salts Chemical class 0.000 title claims 10
- 238000000034 method Methods 0.000 claims 14
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606834 | 2016-04-19 | ||
| PCT/GB2017/051090 WO2017182802A1 (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3445351T3 true FI3445351T3 (fi) | 2024-11-18 |
Family
ID=58633040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17719692.0T FI3445351T3 (fi) | 2016-04-19 | 2017-04-19 | Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10905670B2 (enExample) |
| EP (2) | EP3445351B1 (enExample) |
| JP (3) | JP7387264B2 (enExample) |
| KR (4) | KR102791288B1 (enExample) |
| CN (2) | CN118593463A (enExample) |
| AU (2) | AU2017252507B2 (enExample) |
| BR (1) | BR112018071547A2 (enExample) |
| CA (1) | CA3021155A1 (enExample) |
| DK (1) | DK3445351T3 (enExample) |
| ES (1) | ES2994242T3 (enExample) |
| FI (1) | FI3445351T3 (enExample) |
| HR (1) | HRP20241552T1 (enExample) |
| HU (1) | HUE069219T2 (enExample) |
| IL (3) | IL293266B2 (enExample) |
| LT (1) | LT3445351T (enExample) |
| MD (1) | MD3445351T2 (enExample) |
| MX (2) | MX388461B (enExample) |
| NZ (1) | NZ747307A (enExample) |
| PL (1) | PL3445351T3 (enExample) |
| PT (1) | PT3445351T (enExample) |
| RS (1) | RS66142B1 (enExample) |
| RU (1) | RU2745912C2 (enExample) |
| SG (2) | SG11201809031XA (enExample) |
| SI (1) | SI3445351T1 (enExample) |
| SM (1) | SMT202400459T1 (enExample) |
| WO (1) | WO2017182802A1 (enExample) |
| ZA (1) | ZA201806849B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102791288B1 (ko) * | 2016-04-19 | 2025-04-03 | 인트라바이오 리미티드 | 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염 |
| AU2017308865B2 (en) | 2016-08-11 | 2023-04-13 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| JP7471298B2 (ja) | 2018-12-06 | 2024-04-19 | イントラビオ エルティーディー | アセチル－ロイシンの重水素化類似体 |
| SI3934637T1 (sl) * | 2019-03-02 | 2024-10-30 | Intrabio Ltd Summit House | (N-)acetil-L-levcin za uporabo pri zdravljenju travmatske poškodbe možganov |
| US12171852B1 (en) | 2023-07-18 | 2024-12-24 | Sytheon Ltd | Composition and methods for regulating melanogenesis |
| US12403111B2 (en) | 2024-02-02 | 2025-09-02 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| FR2883180B1 (fr) * | 2005-03-18 | 2007-05-25 | Pierre Fabre Medicament Sa | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| US20080097606A1 (en) * | 2006-10-19 | 2008-04-24 | Cragg Andrew H | Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis |
| EP2152280A1 (en) * | 2007-05-08 | 2010-02-17 | Northern Innovations And Formulations Corp. | Branched-chain amino acid composition for improving skeletal muscle protein metabolism |
| US20120196257A1 (en) * | 2009-08-27 | 2012-08-02 | Joe Verghese | Cognitive function training to improve motor ability |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| WO2012060844A1 (en) * | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| KR102791288B1 (ko) | 2016-04-19 | 2025-04-03 | 인트라바이오 리미티드 | 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염 |
| WO2019079536A1 (en) * | 2017-10-18 | 2019-04-25 | Intrabio Ltd | THERAPEUTIC AGENTS FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION AND FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND LYSOSOMAL STORAGE DISORDERS |
-
2017
- 2017-04-19 KR KR1020247003393A patent/KR102791288B1/ko active Active
- 2017-04-19 KR KR1020187032983A patent/KR20180134398A/ko not_active Ceased
- 2017-04-19 DK DK17719692.0T patent/DK3445351T3/da active
- 2017-04-19 SM SM20240459T patent/SMT202400459T1/it unknown
- 2017-04-19 NZ NZ747307A patent/NZ747307A/en unknown
- 2017-04-19 IL IL293266A patent/IL293266B2/en unknown
- 2017-04-19 PT PT177196920T patent/PT3445351T/pt unknown
- 2017-04-19 JP JP2018555644A patent/JP7387264B2/ja active Active
- 2017-04-19 KR KR1020227008412A patent/KR102413754B1/ko active Active
- 2017-04-19 SI SI201731566T patent/SI3445351T1/sl unknown
- 2017-04-19 CN CN202410876111.2A patent/CN118593463A/zh active Pending
- 2017-04-19 SG SG11201809031XA patent/SG11201809031XA/en unknown
- 2017-04-19 WO PCT/GB2017/051090 patent/WO2017182802A1/en not_active Ceased
- 2017-04-19 EP EP17719692.0A patent/EP3445351B1/en active Active
- 2017-04-19 CA CA3021155A patent/CA3021155A1/en active Pending
- 2017-04-19 US US16/093,780 patent/US10905670B2/en active Active
- 2017-04-19 EP EP24205813.9A patent/EP4501406A3/en active Pending
- 2017-04-19 MD MDE20190248T patent/MD3445351T2/ro unknown
- 2017-04-19 BR BR112018071547-6A patent/BR112018071547A2/pt not_active Application Discontinuation
- 2017-04-19 RS RS20241222A patent/RS66142B1/sr unknown
- 2017-04-19 CN CN201780029480.6A patent/CN109069463B/zh active Active
- 2017-04-19 RU RU2018140131A patent/RU2745912C2/ru active
- 2017-04-19 PL PL17719692.0T patent/PL3445351T3/pl unknown
- 2017-04-19 KR KR1020227021015A patent/KR102632670B1/ko active Active
- 2017-04-19 MX MX2018012739A patent/MX388461B/es unknown
- 2017-04-19 AU AU2017252507A patent/AU2017252507B2/en active Active
- 2017-04-19 LT LTEPPCT/GB2017/051090T patent/LT3445351T/lt unknown
- 2017-04-19 HR HRP20241552TT patent/HRP20241552T1/hr unknown
- 2017-04-19 FI FIEP17719692.0T patent/FI3445351T3/fi active
- 2017-04-19 HU HUE17719692A patent/HUE069219T2/hu unknown
- 2017-04-19 IL IL310508A patent/IL310508A/en unknown
- 2017-04-19 SG SG10202106190RA patent/SG10202106190RA/en unknown
- 2017-04-19 IL IL262379A patent/IL262379B/en unknown
- 2017-04-19 ES ES17719692T patent/ES2994242T3/es active Active
-
2018
- 2018-10-15 ZA ZA2018/06849A patent/ZA201806849B/en unknown
- 2018-10-18 MX MX2021014844A patent/MX2021014844A/es unknown
-
2020
- 2020-12-22 US US17/247,757 patent/US11998518B2/en active Active
-
2021
- 2021-11-12 JP JP2021185130A patent/JP7506046B2/ja active Active
-
2022
- 2022-10-17 AU AU2022256077A patent/AU2022256077A1/en not_active Abandoned
-
2023
- 2023-07-10 US US18/349,221 patent/US12329733B2/en active Active
-
2024
- 2024-06-13 JP JP2024096260A patent/JP2024123087A/ja active Pending
-
2025
- 2025-05-13 US US19/206,473 patent/US20250332133A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3445351T3 (fi) | Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen | |
| MX2024010140A (es) | Nuevos metodos. | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| MX377576B (es) | Formulaciones de pridopidina de liberación modificada. | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MY179696A (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| EA201791199A1 (ru) | Способ лечения болезни альцгеймера | |
| HK1209341A1 (zh) | 與治療柏金遜症相關之運動與動作障礙副作用之治療 | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. | |
| MX380758B (es) | Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo. | |
| EA201790991A1 (ru) | Способ лечения с использованием пегилированного интерферона | |
| MX2021014093A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| MX2020005438A (es) | Formas de dosificacion de sulfato de morfina disuasivas del abuso. | |
| TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
| HK1225969A1 (zh) | 利用低剂量的拉喹莫德治疗克隆氏病 | |
| RU2015122823A (ru) | Способ лечения печёночной энцефалопатии у больных циррозом печени | |
| AR103764A1 (es) | Pridopidina como mejoradora de la función cognitiva y en el tratamiento de la enfermedad de alzheimer | |
| UA115063U (xx) | Спосіб лікування собак із больовим синдромом при панкреатиті | |
| IN2014MU01184A (enExample) | ||
| IN2013MU01155A (enExample) | ||
| IN2014DE00822A (enExample) |